Bristol Myers Squibb reported third-quarter 2026 total revenues of $13.1 billion, representing a 7% increase compared to the same period in 2025. The company raised its full-year 2026 revenue guidance range to $49.75 billion to $50.25 billion, driven by momentum in its Growth Portfolio.
Third-quarter total revenues increased 7% to $13.1 billion compared to $12.2 billion in 2025.
GAAP EPS was $1.05 and non-GAAP EPS was $1.35 for the third quarter of 2026.
Full-year 2026 revenue guidance was raised to a range of $49.75 billion to $50.25 billion.
Non-GAAP EPS guidance for 2026 was updated to a range of $6.35 to $6.55.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Bristol Myers Squibb's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$48.19B
-0.2%
$3.46
—
14.6%
FY2024
$48.30B
+7.3%
$-4.41
-214.2%
-18.5%
FY2023
$45.01B
-2.5%
$3.86
+30.8%
17.8%
FY2022
$46.16B
-0.5%
$2.95
-5.4%
13.7%
FY2021
$46.38B
+9.1%
$3.12
—
15.1%
Frequently asked questions
When is Bristol Myers Squibb's next earnings date?
Bristol Myers Squibb has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Bristol Myers Squibb earn last quarter?
For the quarter ended Sep 2026, Bristol Myers Squibb reported diluted EPS of $1.05 (-2.8% year over year) on revenue of $13.07B (+6.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.